Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Payables (2016 - 2026)

Cytosorbents filings provide 16 years of Payables readings, the most recent being $2.9 million for Q4 2025.

  • On a quarterly basis, Payables fell 14.1% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 million, a 14.1% decrease, with the full-year FY2025 number at $2.9 million, down 14.1% from a year prior.
  • Payables hit $2.9 million in Q4 2025 for Cytosorbents, down from $3.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $4.8 million in Q1 2022 to a low of $1.7 million in Q4 2022.
  • Median Payables over the past 5 years was $2.9 million (2023), compared with a mean of $2.9 million.
  • The widest YoY moves for Payables: up 187.66% in 2022, down 41.0% in 2022.
  • Cytosorbents' Payables stood at $2.8 million in 2021, then tumbled by 41.0% to $1.7 million in 2022, then skyrocketed by 129.71% to $3.8 million in 2023, then fell by 12.16% to $3.3 million in 2024, then dropped by 14.1% to $2.9 million in 2025.
  • The last three reported values for Payables were $2.9 million (Q4 2025), $3.0 million (Q3 2025), and $3.4 million (Q2 2025) per Business Quant data.